Case presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
|
|
|
- Marion Nichols
- 5 years ago
- Views:
Transcription
1 Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department of Radiotherapy Department of Nuclear Medicine Department of Radiology P. De Leyn,W. Coosemans, H. Decaluwé, Ph. Nafteux, D. Van Raemdonck, G. Decker, T. Lerut J. Vansteenkiste, K. Nackaerts, C. Dooms Y. Lievens S. Stroobants W. Dewever year lady 3 months pain in left schoulder and upper arm Antiflogistics Morfine Horner syndrome Medical history 20 packyears 1
2 Chest X-ray CT scan Subclavian artery Investigations Laboratory CEA : 12.2 μg/l (< 3,4 μg/l ) Bronchoscopy : normal Aspirate : normal Transbronchial biopsy : normal Transthoracic puncture : large cell carcinoma Bone scintigraphy : normal PET scan : T positive, N0M0 Pulmonary function test : normal 2
3 Pancoast tumor Diagnosis ct4 (Horner, subclavian artery) N0M0 THERAPY? Further therapy? 1. Chemotherapy 2. Radiotherapy 3. Chemoradiotherapy 4. Induction radiotx + surgery 5. Induction chemoradiotx + surgery Superior sulcus tumours - Pancoast tumor Major challenge : control of locoregional disease Low complete resectability rate despite major procedures Preoperative RT (30-35 Gy) T3N0 : R0 : 66%, T4N0 : R0 : 18%, 5-year survival : 12% Rush et al., J Thorac Cardiovasc Surg 2000;119:
4 Induction chemoradiotherapy for pancoast (SWOG 9416) Inclusion : ct3-t4no (mediast : neg) n=110 Concurrent chemoradiotherapy (cis, etoposide; 45 gy) Surgery in responders and stable disease Rusch et al. J Thorac Cardiovasc Surg, 2001;11: Rusch et al. J Clin Oncol 2007;25: Induction chemoradiotherapy for pancoast (SWOG 9416) Rush et al. J Thorac Cardiovasc Surg, 2001;11: Rush et al. J Clin Oncol 2007;25: Induction chemoradiotherapy for pancoast (SWOG 9416) Complete resectability : 75% Pathological complete response or minimal microscopic disease : 65% Overall survival (5-yr) : 44% Survival in R0 resections (5-yr) : 54% Rusch et al. J Thorac Cardiovasc Surg, 2001;11: Rusch et al. J Clin Oncol 2007;25:
5 Induction chemoradiotherapy for pancoast (SWOG 9416) 54% (R0 resections) Rusch et al. J Thorac Cardiovasc Surg, 2001;11: Rusch et al. J Clin Oncol 2007;25: : Cervical mediastinoscopy Negative at levels 7, 4L, 4R and 2R Concommitant chemoradiotherapy (start ) Cisplatin-etoposide (2 courses) 45 gy (25 fractions of 1.8 gy) Reevaluation No pain CT : yt4n0m0 CT after induction chemoradiotx yt4n0m0 5
6 CT after induction chemoradiotx yt4n0m0 Further therapy? 1. Surgery 2. Further radiotherapy 3. Stop therapy : Left posterolateral thoracotomy (Paulson incision) Upper lobectomy + chest wall resection (rib 1 + 2). No reconstruction of chest wall Pathology : fibrosis +++ Some small islands of viable tumor pt2n0m0, complete resection 6
7 Giant cell Sclerosis, macrophages Necrosis Cholesterol Viable tumor cells Giant cell Sclerosis, macrophages, cholesterol CT scan is poor predictor of response SWOG 9416 ct3-t4n0m0 pancoast tumors (n=110) Complete resectability : 75% 65% of specimens showed a pathologic complete response or minimal microscopic disease 32 (36%) pathologic complete response 17 partial response on CT 15 stable disease on CT Rusch et al. J Thorac Cardiovasc Surg, 2001;11: Rusch et al. J Clin Oncol 2007;25:
8 No postoperative problems (hospital stay : 11 days) 2 adjuvant courses of cisplatinum-etoposide (start ) March 2008 : No evidence of disease (CEA : 1,6 μg/l) Materials and methods April 2002 februari patients (prospective, consecutive) ct4 tumor (17) Pancoast 15 (ct3-4) ct4 Pulmonary artery : 5 Atrium : 5 Aorta : 3 Extens mediastinal infiltration : 2 Recurrent laryngeal nerve : 1 Subclavian artery : 1 Pancoast ct3 : 5 ct4 : 10 N0 M0 (PET or CT/PET and mediastinoscopy) De Leyn et al, J Thorac Oncol 2009;4:62-8 De Leyn et al, J Thorac Oncol 2009;4:62-8 8
9 Postoperative morbidity/mortality Mean hospital stay : 9.2 days No hospital mortality ICU : 1 patient No bronchopleural fistulae or empyema De Leyn et al, J Thorac Oncol 2009;4:62-8 De Leyn et al, J Thorac Oncol 2009;4: % 60% De Leyn et al, J Thorac Oncol 2009;4:62-8 9
10 Remaining questions Improve induction therapy? Increase radiation dose Hyperfractionated accelerated RT Third-generation chemotherapy? Profyllactic cranial irradiation? High dose radiotherapy in trimodality treatment of pancoast tumors N = 36 Preoperative chemoradiation (mean total radiation dose : 56.9 gy) R0 resection : 97% Pathological CR : 40% Operative mortality : 2.7% Kwong et al, J Thorac Cardiovasc Surg 2005;129: Prohyllactic Cranial irradiation? Single site brain metastasis is most common site of recurrence (>40%) Significant reduction in incidence of brain metastasis in patients with operable stage-iiia NSCLC undergoing trimodal treatment Control : 35% PCI : 7.8% Rusch et al. J Clin Oncol 2007;25: Kwong et al, J Thorac Cardiovasc Surg 2005;129: Pöttgen et al., J Clin Oncol 2007;25:
11 Conclusion Trimodality treatment is feasible with low morbidity and mortality High complete resectablity CT scan is poor predictor of response. Both patients with response or stable disease on CT should be explored Prophyllactic PCI? Multidisciplinary approach K.U. Leuven, Belgium University Hospital Gasthuisberg Leuven Lung Cancer Group ( 11
Tumors of the superior sulcus and central T4 tumors are an
ORIGINAL ARTICLE Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer Paul De Leyn, MD, PhD,* Johan Vansteenkiste, MD, PhD, Yolande Lievens, MD, PhD, Dirk
HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
Multifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
MEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
THORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
Adam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
Induction Chemoradiation Therapy with Cisplatin plus Irinotecan Followed by Surgical Resection for Superior Sulcus Tumor
Original Article Induction Chemoradiation Therapy with Cisplatin plus Irinotecan Followed by Surgical Resection for Superior Sulcus Tumor Katsuhiko Shimizu, 1 Masao Nakata, 1 Ai Maeda, 1 Takuro Yukawa,
Heterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
Small cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
Resection of the First Rib With Preservation of the T1 Nerve Root in Pancoast Tumors of the Lung
Special Report Resection of the First Rib With Preservation of the T1 Nerve Root in Pancoast Tumors of the Lung Andreas K. Filis, MD, Lary A. Robinson, MD, and Frank D. Vrionis, MD, PhD Background: Surgical
Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
Charles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
The surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
Early and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
Pneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
Mediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
Short-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer
Short-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer Thomas W. Rice, MD, David J. Adelstein, MD, Jay P. Ciezki, MD, Mark E. Becker, MD, Lisa A. Rybicki, MS,
Surgical Approaches to Locally Advanced NSCLC. Kemp H. Kernstine, MD, PhD Professor and Chairman UT Southwestern Medical Center Dallas, TX
Surgical Approaches to Locally Advanced NSCLC Kemp H. Kernstine, MD, PhD Professor and Chairman UT Southwestern Medical Center Dallas, TX Keep it real simple. Do one thing and do it the best you can. -Harry
Clinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
The eponym Pancoast tumor derives from the noted Philadelphia radiologist
General Thoracic Surgery Kwong et al High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival King F. Kwong,
Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
LUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
VATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
Combining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
Video-Mediastinoscopy Thoracoscopy (VATS)
Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin
Protocol of Radiotherapy for Small Cell Lung Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Small Cell Lung Cancer Indication of radiotherapy Limited stage: AJCC (8th edition) stage I-III (T any, N any, M0) that can be safely treated with definitive RT
Bronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
MINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER: where do we stand?
MINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER: where do we stand? Ph Nafteux, MD Copenhagen, Nov 3rd 2011 Department of Thoracic Surgery, University Hospitals Leuven, Belgium W. Coosemans, H. Decaluwé, Ph.
Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
According to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
Surgical Treatment of Lung Cancer with Vertebral Invasion
Original Article Surgical Treatment of Lung Cancer with Vertebral Invasion Kiyoshi Koizumi, MD, Shuji Haraguchi, MD, Tomomi Hirata, MD, Kyoji Hirai, MD, Iwao Mikami, MD, Shigeki Yamagishi, MD, Daisuke
The right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
surgical approach for resectable NSCLC
surgical approach for resectable NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France 1933 Graham EA, Singer JJ.
An Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
Lung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
Lung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
Non-small cell lung cancer involving the superior sulcus
Management of Superior Sulcus Tumors: Posterior Approach Daniel G. Cuadrado, MD,*, and Eric L. Grogan, MD, MPH*, Non-small cell lung cancer involving the superior sulcus represents less than 5% of patients
T3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
Adjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
Special Treatment Issues in Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Special Treatment Issues in Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College
Non small-cell lung cancers (NSCLCs) located along
Original Article Long-Term Outcome after En Bloc Resection of Non Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine Stéphane Collaud, MD, MSc,* Thomas K. Waddell, MD, PhD,* Kazuhiro Yasufuku,
Patients with pathologically diagnosed involved mediastinal
MINI-SYMPOSIUM ON EMERGING TECHNIQUES FOR LUNG CANCER STAGING European Trends in Preoperative and Intraoperative Nodal Staging: ESTS Guidelines P. De Leyn, MF, PhD,* D. Lardinois, MD, P. Van Schil, MD,
LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion
Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion Pieter Postmus The Clatterbridge Cancer Centre Liverpool Heart and Chest Hospital Liverpool, United Kingdom 1 2
The Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
Induction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
Surgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
Is neoadjuvant chemotherapy mandatory for limited-disease small-cell lung cancer?
Interactive CardioVascular and Thoracic Surgery Advance Access published August 24, 2014 Interactive CardioVascular and Thoracic Surgery (2014) 1 7 doi:10.1093/icvts/ivu262 THORACIC Is neoadjuvant chemotherapy
Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
Radiotherapy Planning (Contouring Lung Cancer for Radiotherapy dose prescription) Dr Raj K Shrimali
Radiotherapy Planning (Contouring Lung Cancer for Radiotherapy dose prescription) Dr Raj K Shrimali Let us keep this simple and stick to some basic rules Patient positioning Must be reproducible Must be
Chemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
Surgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
Lung cancer is the leading cause of cancer-related
Advanced Non-Small Cell Lung Cancer: Induction Chemotherapy and Chemoradiation Before Operation Arnold Cyjon, MD, Moshe Nili, MD, Gershon Fink, MD, Mordechai R. Kramer, MD, Eyal Fenig, MD, Judith Sandbank,
Impact of trimodality treatment on patient quality of life and arm function for superior sulcus tumors
Impact of trimodality treatment on patient quality of life and arm function for superior sulcus tumors Cornelis G Vos, MD, PhD, a Ramon R Gorter, MD, a Koen J Hartemink, MD, PhD, ab and J Wolter A Oosterhuis,
Combined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
Two cases of combined thoracoscopy and open chest surgery for locally advanced lung carcinoma
rief Report Two cases of combined thoracoscopy and open chest surgery for locally advanced lung carcinoma Hitoshi Dejima, Hiroaki Kuroda, Katsutoshi Seto, Shozo Sakata, Takaaki rimura, Tetsuya Mizuno,
ORIGINAL ARTICLE. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 43 (2013) e71 e81 doi:10.1093/ejcts/ezs622 Advance Access publication 4 January 2013 ORIGINAL ARTICLE a b c d Long-term results in patients with pathological
N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten. W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.
N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.Senan Submitted 10 Salvage surgery for local failures after stereotactic
and Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
History of Surgery for Lung Cancer
Welcome to Master Class for Oncologists Session 1: 7:30 AM - 8:15 AM San Francisco, CA October 23, 2009 Innovations in The Surgical Treatment of Lung Cancer Speaker: Scott J. Swanson, MD 2 Presenter Disclosure
Self-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
Is the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael S. Mulligan, MD, Renato G. Martins, MD, Brenda F.
Index. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
Lung cancer with chest wall involvement: Predictive factors of long-term survival after surgical resection
Lung Cancer (2006) 52, 359 364 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/lungcan Lung cancer with chest wall involvement: Predictive factors of long-term survival after
THORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS
THORACIK RICK Outline and objectives Lungs Management of a solitary lung nodule Mediastinum Management of a mediastinal mass Pleura Management of a pleural fluid & pneumothorax Esophagus & Stomach Management
A Phase II Single-Institution Study of Neoadjuvant Stage III A/B Chemotherapy and Radiochemotherapy in Non-Small Cell Lung Cancer
A Phase II Single-Institution Study of Neoadjuvant Stage III A/B Chemotherapy and Radiochemotherapy in Non-Small Cell Lung Cancer Andreas Granetzny, MD, Eberhard Striehn, MD, Ulrich Bosse, MD, Wolfgang
Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
Aravot et al. Journal of Cardiothoracic Surgery (2019) 14:7 https://doi.org/10.1186/s13019-018-0829-z RESEARCH ARTICLE Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting
Induction chemoradiotherapy facilitates radical resection of T4 non small cell lung cancer invading the spine
Anraku et al General Thoracic Surgery Induction chemoradiotherapy facilitates radical resection of T4 non small cell lung cancer invading the spine Masaki Anraku, MD, a Thomas K. Waddell, MD, a Marc de
Lung cancer LUNG CANCER. Box 1 Clinical signs
22 LUNG CANCER Lung cancer Bronchial carcinoma refers to two distinct clinical entities small cell and non-small cell carcinoma. Although these conditions have much in common, with broadly similar presenting
Thoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy
Lung Cancer Update. HARMESH R NAIK, MD. February 28, 2001
Lung Cancer Update HARMESH R NAIK, MD. February 28, 2001 Progress update Prevention Screening Staging Treatment Epidemiology Estimated 169,500 new cases Estimated 157,400 deaths Second commonest cancer
Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer
Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer Robert J. Cerfolio, MD, Ayesha S. Bryant, MSPH, Thomas S. Winokur, MD, Buddhiwardhan
The role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
The tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
The Role of Radiation Therapy
The Role of Radiation Therapy and Surgery in the Treatment of Bronchogenic Carcinoma R Adams Cowley, M.D., Morris J. Wizenberg, M.D., and Eugene J. Linberg, M.D. A study of the combined use of preoperative
Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
Neoadjuvant Chemoradiation for Clinically Advanced Non-Small Cell Lung Cancer: An Analysis of 233 Patients
Neoadjuvant Chemoradiation for Clinically Advanced Non-Small Cell Lung Cancer: An Analysis of 233 Patients Anthony W. Kim, MD, Michael J. Liptay, MD, Philip Bonomi, MD, William H. Warren, MD, Sanjib Basu,
Are we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
Advances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
Cécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010
Prophylactic Cranial Irradiation in Lung Cancer Cécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010 Prophylactic cranial irradiation PCI was introduced